{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:47:48Z","timestamp":1785822468655,"version":"3.56.0"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PI19\/01277"],"award-info":[{"award-number":["PI19\/01277"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["CPP 2022-009808"],"award-info":[{"award-number":["CPP 2022-009808"]}],"id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["CEX 2020-001024-S\/ AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["CEX 2020-001024-S\/ AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-2023-ADG 101142260"],"award-info":[{"award-number":["ERC-2023-ADG 101142260"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d'Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["2025 FI-1 01043"],"award-info":[{"award-number":["2025 FI-1 01043"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell Dev. Biol."],"abstract":"<jats:p>\n                    Melanoma, the most aggressive form of skin cancer, arises from malignantly transformed melanocytes. Its incidence and mortality are increasing despite the enormous advances in both the knowledge of the disease and the development of effective therapies. From a genetic point of view, cutaneous melanoma can be classified as driven by mutations in\n                    <jats:italic>BRAF<\/jats:italic>\n                    ,\n                    <jats:italic>NRAS<\/jats:italic>\n                    or\n                    <jats:italic>NF1<\/jats:italic>\n                    , or the absence of these mutations (triple wildtype).\n                    <jats:italic>MYC<\/jats:italic>\n                    , an oncogene deregulated in most human cancers, drives tumor progression by exerting a broad array of functions that affect all the hallmarks of cancer. In this context, increased MYC activity in melanoma patients occurs by amplification of its gene locus, or by upstream signaling leading to its stabilization and overexpression. In this review, we discuss the role of MYC in melanoma, its relationship with the response and resistance to both targeted therapies and immunotherapy, the different approaches that have been tested to target MYC in this disease, and finally, the future directions towards MYC becoming a target in melanoma.\n                  <\/jats:p>","DOI":"10.3389\/fcell.2026.1750941","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:39:18Z","timestamp":1785821958000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["MYC as a key target for melanoma therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Manuel","family":"Lillo-Valero","sequence":"first","affiliation":[{"name":"Models of Cancer Therapies Group, Vall d\u2019Hebron Institute of Oncology (VHIO), Instituto de Investigaci\u00f3n Sanitaria Hospital Universitari Vall d\u2019Hebron (IIS IR-HUVH), Vall d\u2019Hebron Barcelona Hospital Campus","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano F.","family":"Zacar\u00edas-Fluck","sequence":"additional","affiliation":[{"name":"Models of Cancer Therapies Group, Vall d\u2019Hebron Institute of Oncology (VHIO), Instituto de Investigaci\u00f3n Sanitaria Hospital Universitari Vall d\u2019Hebron (IIS IR-HUVH), Vall d\u2019Hebron Barcelona Hospital Campus","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Soucek","sequence":"additional","affiliation":[{"name":"Models of Cancer Therapies Group, Vall d\u2019Hebron Institute of Oncology (VHIO), Instituto de Investigaci\u00f3n Sanitaria Hospital Universitari Vall d\u2019Hebron (IIS IR-HUVH), Vall d\u2019Hebron Barcelona Hospital Campus","place":["Barcelona, Spain"]},{"name":"Peptomyc S.L., Vall D\u2019Hebron Barcelona Hospital Campus","place":["Barcelona, Spain"]},{"name":"Department of Biochemistry and Molecular Biology, Universitat Aut\u00f2noma de Barcelona","place":["Bellaterra, Spain"]},{"name":"Instituci\u00f3 Catalana de Recerca I Estudis Avan\u00e7ats (ICREA)","place":["Barcelona, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/j.1751-1097.2008.00294.x","article-title":"The melanocortin 1 receptor and the UV response of human melanocytes\u2014A shift in paradigm","volume":"84","author":"Abdel\u2010Malek","year":"2008","journal-title":"Photochem. Photobiol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-20-1707","article-title":"A phase Ib\/IIa study of the Pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer","volume":"26","author":"Aggarwal","year":"2020","journal-title":"Clin. Cancer Research An Official Journal Am. Assoc. Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"e0180147","DOI":"10.1371\/journal.pone.0180147","article-title":"Sequence-specific DNA binding by MYC\/MAX to low-affinity non-E-box motifs","volume":"12","author":"Allevato","year":"2017","journal-title":"PLOS ONE"},{"key":"B4","unstructured":"The role of BRAF V600 mutation in melanoma\n          \n          \n            \n              Ascierto\n              P. A.\n            \n            \n               Kirkwood\n              J. M.\n            \n            \n              Grob\n              J. -J.\n            \n            \n              Simeone\n              E.\n            \n            \n              Grimaldi\n              A. M.\n            \n            \n              Maio\n              M.\n            \n          \n          \n          2012"},{"key":"B5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/imt-2018-0208","article-title":"Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF -mutant advanced melanoma: a matching-adjusted indirect comparison","volume":"11","author":"Atkins","year":"2019","journal-title":"Immunotherapy"},{"key":"B6","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/356713a0","article-title":"Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients","volume":"356","author":"Basu","year":"1992","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/pcmr.12885","article-title":"Acral lentiginous melanoma: basic facts, biological characteristics and research perspectives of an understudied disease","volume":"34","author":"Basurto\u2010Lozada","year":"2021","journal-title":"Pigment Cell. and Melanoma Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1101\/gad.1024602","article-title":"c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression","volume":"16","author":"Baudino","year":"2002","journal-title":"Genes. and Dev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.3390\/cells9041038","article-title":"Structural and biophysical insights into the function of the intrinsically disordered myc oncoprotein","volume":"9","author":"Beaulieu","year":"2020","journal-title":"Cells"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-04-1582","article-title":"Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins","volume":"11","author":"Bucci","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","year":"2015","journal-title":"Cell."},{"key":"B12","doi-asserted-by":"publisher","first-page":"100947","DOI":"10.1016\/j.neo.2023.100947","article-title":"Acral melanoma: new insights into the immune and genomic landscape","volume":"46","author":"Carvalho","year":"2023","journal-title":"Neoplasia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1182\/blood-2017-11-742577","article-title":"The MYC oncogene is a global regulator of the immune response","volume":"131","author":"Casey","year":"2018","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.3390\/cancers15164026","article-title":"BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers","volume":"15","author":"Castellani","year":"2023","journal-title":"Cancers"},{"key":"B15","first-page":"372","article-title":"The journey from melanocytes to melanoma","volume-title":"Nat. Rev. Cancer.","author":"Centeno","year":"2023"},{"key":"B16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/00000637-200108000-00011","article-title":"The prognostic importance of c-myc oncogene expression in head and neck melanoma","volume":"47","author":"Chana","year":"2001","journal-title":"Ann. Plastic Surg."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/nejmoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1002\/cncr.29727","article-title":"Uveal melanoma: from diagnosis to treatment and the science in between","volume":"122","author":"Chattopadhyay","year":"2016","journal-title":"Cancer"},{"key":"B19","first-page":"283","article-title":"c-myc antisense oligodeoxynucleotides enhance the efficacy of cisplatin in melanoma chemotherapy in vitro and in nude mice","volume":"58","author":"Citro","year":"1998","journal-title":"Cancer Research"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1182\/blood.2020007193","article-title":"Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC","volume":"137","author":"Collinge","year":"2021","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"5771","DOI":"10.1038\/onc.2017.189","article-title":"Melanocytic nevi and melanoma: unraveling a complex relationship","volume":"36","author":"Damsky","year":"2017","journal-title":"Oncogene"},{"key":"B22","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"Dang","year":"2012","journal-title":"Cell."},{"key":"B23","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"B24","doi-asserted-by":"publisher","first-page":"7538","DOI":"10.1158\/1078-0432.CCR-09-1985","article-title":"Integrated molecular and clinical analysis of AKT activation in metastatic melanoma","volume":"15","author":"Davies","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene \u2014 the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1186\/s12885-024-12426-z","article-title":"Patterns and trends in melanoma mortality in the United States, 1999-2020","volume":"24","author":"Didier","year":"2024","journal-title":"BMC Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1002\/1878-0261.13319","article-title":"MYC and therapy resistance in cancer: risks and opportunities","volume":"16","author":"Donati","year":"2022","journal-title":"Mol. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1200\/PO.21.00084","article-title":"Positive association between location of melanoma, ultraviolet signature, tumor mutational burden, and response to Anti\u2013PD-1 therapy","author":"Dousset","year":"2021","journal-title":"JCO Precis. Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/sj.onc.1204392","article-title":"Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27kip1 levels","volume":"20","author":"D\u2019Agnano","year":"2001","journal-title":"Oncogene"},{"key":"B29","volume-title":"Zelboraf European Medicines Agency EMA (2018)","year":"2012"},{"key":"B30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1758834015616934","article-title":"Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy","volume":"8","author":"Eroglu","year":"2016","journal-title":"Ther. Advances Medical Oncology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12964-018-0262-x","article-title":"Nrf2 activation drive macrophages polarization and cancer cell epithelial-mesenchymal transition during interaction","volume":"16","author":"Feng","year":"2018","journal-title":"Cell. Commun. Signal."},{"key":"B32","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/s41591-024-02805-1","article-title":"MYC targeting by OMO-103 in solid tumors: a phase 1 trial","volume":"30","author":"Garralda","year":"2024","journal-title":"Nat. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/jcm9010223","article-title":"Anti-PD-1 and novel combinations in the treatment of melanoma\u2014an update","volume":"9","author":"Gellrich","year":"2020","journal-title":"J. Clin. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1738440","DOI":"10.3389\/fimmu.2026.1738440","article-title":"MYC at the tumor\u2013immune interface: mechanisms of immune escape and immunotherapy resistance","volume":"17","author":"Gonz\u00e1lez-Larreategui","year":"2026","journal-title":"Front. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jmoldx.2012.10.002","article-title":"Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma","volume":"15","author":"Greaves","year":"2013","journal-title":"J. Molecular Diagnostics JMD"},{"key":"B36","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0748-7983(96)90154-7","article-title":"C-myc oncogene expression in human melanoma and its relationship with tumour antigenicity","volume":"22","author":"Grover","year":"1996","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1097\/01.SAP.0000032308.89737.EA","article-title":"Use of oncogene expression as an independent prognostic marker for primary melanoma","volume":"50","author":"Grover","year":"2003","journal-title":"Ann. Plastic Surg."},{"key":"B38","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ccell.2019.10.001","article-title":"Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy","volume":"36","author":"Han","year":"2019","journal-title":"Cancer Cell."},{"key":"B39","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s43018-022-00494-8","article-title":"HDAC6 score: to treat or not to treat?","volume":"4","author":"Hey","year":"2022","journal-title":"Nat. Cancer"},{"key":"B40","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B41","unstructured":"A study evaluating the safety and efficacy of targeted therapies in subpopulations of patients with metastatic colorectal cancer (INTRINSIC), NCT04929223\n          \n          \n          2026"},{"key":"B42","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/1523-1747.ep12505549","article-title":"Comparison of cellular protooncogene activation and transformation-related activity of human melanocytes and metastatic melanoma","volume":"95","author":"Husain","year":"1990","journal-title":"J. Investigative Dermatology"},{"key":"B43","unstructured":"A phase 1\/\u200b2 Studysof IDP-121 in Patiepts With welapsed\/Refractory Hematologih Malignancims (CASSANDRA)\n          \n          \n            \n              Idp Discovery Pharma\n              S. L.\n            \n          \n          \n          2025"},{"key":"B44","unstructured":"ACY-1215 in combination with BCR pathway inhibitors in relapsed CLL, NCT02787369\n          \n          \n            \n              Jennifer\n              R.\n            \n            \n              Brown\n              M. P.\n            \n          \n          \n          2026"},{"key":"B45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.2217\/mmt.15.40","article-title":"NRAS mutant melanoma: an overview for the clinician for melanoma management","volume":"3","author":"Jenkins","year":"2016","journal-title":"Melanoma Management"},{"key":"B46","doi-asserted-by":"publisher","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-14-0776","article-title":"FDA approval summary: Vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation","volume":"20","author":"Kim","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.cell.2017.11.013","article-title":"Myc cooperates with ras by programming inflammation and immune suppression","volume":"171","author":"Kortlever","year":"2017","journal-title":"Cell."},{"key":"B48","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1054\/bjoc.2000.1535","article-title":"Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases","volume":"84","author":"Kraehn","year":"2001","journal-title":"Br. J. Cancer"},{"key":"B49","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10014-025-00506-2","article-title":"Integrated analysis of MYC expression, 8q24.21 copy number, and recurrence patterns in astrocytoma, IDH-Mutant","volume":"42","author":"Kumon","year":"2025","journal-title":"Brain Tumor Pathol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1038\/s41467-024-47425-y","article-title":"Molecular patterns of resistance to immune checkpoint blockade in melanoma","volume":"15","author":"Lauss","year":"2024","journal-title":"Nat. Commun."},{"key":"B53","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/BF00193169","article-title":"Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma","volume":"426","author":"Lazaris","year":"1995","journal-title":"Virchows Arch."},{"key":"B54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.yexcr.2014.09.019","article-title":"Replication stress and cancer: it takes two to tango","volume":"329","author":"Lecona","year":"2014","journal-title":"Exp. Cell. Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/sj.cgt.7700326","article-title":"Encapsulation of c-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line","volume":"8","author":"Leonetti","year":"2001","journal-title":"Cancer Gene Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41420-023-01403-3","article-title":"The effects of MYC on tumor immunity and immunotherapy","volume":"9","author":"Li","year":"2023","journal-title":"Cell. Death Discov."},{"key":"B57","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600\u2013Mutant metastatic melanoma receiving dabrafenib combined with trametinib","volume":"34","author":"Long","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.3390\/cancers14194652","article-title":"Melanoma management: from epidemiology to treatment and latest advances cancers","volume":"14","author":"Lopes","year":"2022","journal-title":"MDPI"},{"key":"B59","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.tranon.2017.07.008","article-title":"A novel IMP1 inhibitor, BTYNB, targets c-Myc and inhibits melanoma and ovarian cancer cell proliferation","volume":"10","author":"Mahapatra","year":"2017","journal-title":"Transl. Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1093\/jnci\/djg123","article-title":"Determinants of BRAF mutations in primary melanomas","volume":"95","author":"Maldonado","year":"2003","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"B61","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1158\/2326-6066.CIR-22-0184","article-title":"MYC induces immunotherapy and IFN\u03b3 resistance through downregulation of JAK2","volume":"11","author":"Markovits","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"883","DOI":"10.3390\/cells9040883","article-title":"Blocking myc to treat cancer: reflecting on two decades of omomyc","volume":"9","author":"Mass\u00f3-Vall\u00e9s","year":"2020","journal-title":"Cells"},{"key":"B116","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41698-025-01230-y","article-title":"Prospective tumour mutation burden and neoantigen profiling predicts immunotherapy response in metastatic melanoma","volume":"10","author":"Mao","year":"2026","journal-title":"npj Precis. Onc."},{"key":"B63","doi-asserted-by":"publisher","first-page":"5219","DOI":"10.3390\/cancers13205219","article-title":"Mutational characterization of cutaneous melanoma supports divergent pathways model for melanoma development","volume":"13","author":"Mill\u00e1n-Esteban","year":"2021","journal-title":"Cancers"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1158\/1078-0432.CCR-07-4068","article-title":"Detection of copy number alterations in metastatic melanoma by a DNA fluorescence in situ hybridization probe panel and array comparative genomic hybridization: a southwest oncology group study (S9431)","volume":"14","author":"Moore","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e2982","DOI":"10.1038\/cddis.2017.383","article-title":"BET bromodomain inhibitors synergize with ATR inhibitors in melanoma","volume":"8","author":"Muralidharan","year":"2017","journal-title":"Cell. Death and Dis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.ccr.2008.10.018","article-title":"Distinct thresholds govern myc\u2019s biological output in vivo","volume":"14","author":"Murphy","year":"2008","journal-title":"Cancer Cell."},{"key":"B67","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0092-8674(02)01284-9","article-title":"X-Ray structures of myc-max and mad-max recognizing DNA","volume":"112","author":"Nair","year":"2003","journal-title":"Cell."},{"key":"B68","volume-title":"Dinaciclib in Treating Patients with Stage IV Melanoma","year":"2026"},{"key":"B69","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1158\/2159-8290.CD-22-0603","article-title":"Comparative genomics provides etiologic and biological insight into melanoma subtypes","volume":"12","author":"Newell","year":"2022","journal-title":"Cancer Discov."},{"key":"B70","doi-asserted-by":"publisher","first-page":"37304","DOI":"10.31083\/FBL37304","article-title":"The role of MYC in tumor immune microenvironment regulation: insights and future directions","volume":"30","author":"Nirala","year":"2025","journal-title":"Front. Bioscience-Landmark"},{"key":"B117","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41416-025-03048-8","article-title":"Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab","volume":"133","author":"Noringriis","year":"2025","journal-title":"Br. J. Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/1523-1747.ep12340688","article-title":"Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes","volume":"106","author":"Ohta","year":"1996","journal-title":"J. Investigative Dermatology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1034\/j.1600-0625.2002.110507.x","article-title":"Effect of the transcriptional repressor Mad1 on proliferation of human melanoma cells","volume":"11","author":"Ohta","year":"2002","journal-title":"Exp. Dermatol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/j.1346-8138.1992.tb03799.x","article-title":"The neurofibromatosis type 1 (NF1) gene: identification and partial characterization of a putative tumor suppressor gene","volume":"19","author":"O\u2019Connell","year":"1992","journal-title":"J. Dermatology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2217\/nnm.14.101","article-title":"A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy","volume":"10","author":"Pan","year":"2015","journal-title":"Nanomedicine"},{"key":"B75","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-024-02031-w","article-title":"Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma","volume":"23","author":"Park","year":"2024","journal-title":"Mol. Cancer"},{"key":"B76","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jconrel.2007.11.010","article-title":"Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin","volume":"126","author":"Pastorino","year":"2008","journal-title":"J. Control. Release"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3390\/genes12071077","article-title":"The interplay between nevi and melanoma predisposition unravels nevi-related and nevi-resistant familial melanoma","volume":"12","author":"Pellegrini","year":"2021","journal-title":"Genes."},{"key":"B78","doi-asserted-by":"publisher","first-page":"14","DOI":"10.20517\/cdr.2024.213","article-title":"Unraveling BRAF alterations: molecular insights to circumvent therapeutic resistance across cancer types","volume":"8","author":"Perfetto","year":"2025","journal-title":"Cancer Drug Resistance (Alhambra, Calif.)"},{"key":"B79","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s42764-020-00009-8","article-title":"Mechanisms of UV-induced mutations and skin cancer","volume":"1","author":"Pfeifer","year":"2020","journal-title":"Genome Instability and Disease"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1038\/modpathol.2012.75","article-title":"The role of 8q24 copy number gains and c-MYC expression in amelanotic cutaneous melanoma","volume":"25","author":"Pouryazdanparast","year":"2012","journal-title":"Mod. Pathol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1128\/MCB.01341-10","article-title":"The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3","volume":"31","author":"Rahman","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/j.clinthera.2012.06.009","article-title":"Vemurafenib in patients with BRAF V600E mutation\u2013positive advanced melanoma","volume":"34","author":"Ravnan","year":"2012","journal-title":"Clin. Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"10153","DOI":"10.1038\/ncomms10153","article-title":"BPTF is required for c-MYC transcriptional activity and in vivo tumorigenesis","volume":"7","author":"Richart","year":"2016","journal-title":"Nat. Commun."},{"key":"B84","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1046\/j.1365-2168.1998.00528.x","article-title":"Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma","volume":"85","author":"Ross","year":"1998","journal-title":"J. Br. Surg."},{"key":"B86","doi-asserted-by":"publisher","first-page":"29159","DOI":"10.1038\/srep29159","article-title":"Topical and targeted delivery of siRNAs to melanoma cells using a fusion peptide carrier","volume":"6","author":"Ruan","year":"2016","journal-title":"Sci. Rep."},{"key":"B87","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.crimmu.2021.08.002","article-title":"Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape","volume":"2","author":"Sarkar","year":"2021","journal-title":"Curr. Res. Immunol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"e013063","DOI":"10.1136\/jitc-2025-013063","article-title":"Stress-NRF2 response axis polarizes tumor macrophages and undermines immunotherapy","volume":"13","author":"Schaer","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"eabg4498","DOI":"10.1126\/sciadv.abg4498","article-title":"Rejection of benign melanocytic nevi by nevus-resident CD4 + T cells","volume":"7","author":"Schiferle","year":"2021","journal-title":"Sci. Adv."},{"key":"B118","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1046\/j.1523-1747.1999.00506.x","article-title":"Influence of increased c-Myc expression on the growth characteristics of human melanoma","volume":"112","author":"Schlagbauer-Wadl","year":"1999","journal-title":"J Invest Dermatol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"6264","DOI":"10.1158\/0008-5472.CAN-13-0122-T","article-title":"BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy","volume":"73","author":"Segura","year":"2013","journal-title":"Cancer Res."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The genetic evolution of melanoma from precursor lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1021\/acs.jmedchem.0c00628","article-title":"Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1 H-pyrrolo[2,3- c]pyridine-2-carboxamide (ABBV-744), a BET bromodomain inhibitor with selectivity for the second bromodomain","volume":"63","author":"Sheppard","year":"2020","journal-title":"J. Med. Chem."},{"key":"B94","first-page":"1117","article-title":"Aberrant oncogene expression in uncultured human sarcoma and melanoma","volume":"7","author":"Shin","year":"1987","journal-title":"Anticancer Research"},{"key":"B95","doi-asserted-by":"publisher","first-page":"11593","DOI":"10.1073\/pnas.182256799","article-title":"Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c- MYC transcription","volume":"99","author":"Siddiqui-Jain","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/j.celrep.2017.11.022","article-title":"Melanoma therapeutic strategies that select against resistance by exploiting MYC-driven evolutionary convergence","volume":"21","author":"Singleton","year":"2017","journal-title":"Cell. Rep."},{"key":"B97","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600\u2013Mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"B98","doi-asserted-by":"publisher","first-page":"6395","DOI":"10.3390\/ijms22126395","article-title":"Aetiology and pathogenesis of cutaneous melanoma: current concepts and advances","volume":"22","author":"Strashilov","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B99","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/B978-0-12-386469-7.00004-9","article-title":"Proteolytic control of the oncoprotein transcription factor myc","volume":"110","author":"Thomas","year":"2011","journal-title":"Adv. Cancer Research"},{"key":"B100","doi-asserted-by":"publisher","first-page":"5463","DOI":"10.1038\/s41467-020-19075-3","article-title":"Combating acquired resistance to MAPK inhibitors in melanoma by targeting Abl1\/2-mediated reactivation of MEK\/ERK\/MYC signaling","volume":"11","author":"Tripathi","year":"2020","journal-title":"Nat. Commun."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1002\/ijc.35087","article-title":"Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling","volume":"155","author":"Turner","year":"2024","journal-title":"Int. J. Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1081\/CNV-120005904","article-title":"Expression of c-myc and bcl-2 in primary and advanced cutaneous melanoma","volume":"20","author":"Utikal","year":"2002","journal-title":"Cancer Investig."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1002\/j.1460-2075.1988.tb02909.x","article-title":"c-myc down-regulates class I HLA expression in human melanomas","volume":"7","author":"Versteeg","year":"1988","journal-title":"EMBO J."},{"key":"B104","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13073-022-01068-0","article-title":"Integrated genomic analyses of acral and mucosal melanomas nominate novel driver genes","volume":"14","author":"Wang","year":"2022","journal-title":"Genome Med."},{"key":"B105","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/CM9.0000000000003416","article-title":"Recent global patterns in skin cancer incidence, mortality, and prevalence","volume":"138","author":"Wang","year":"2025","journal-title":"Chin. Med. J."},{"key":"B106","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-025-01143-2","article-title":"MYC in cancer: from undruggable target to clinical trials","volume":"24","author":"Whitfield","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"B107","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2407417","article-title":"Final, 10-Year outcomes with nivolumab plus ipilimumab in advanced melanoma","volume":"392","author":"Wolchok","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"103866","DOI":"10.1016\/j.bioorg.2020.103866","article-title":"A drug-like imidazole-benzothiazole conjugate inhibits malignant melanoma by stabilizing the c-MYC G-quadruplex","volume":"99","author":"Wu","year":"2020","journal-title":"Bioorg. Chem."},{"key":"B109","doi-asserted-by":"publisher","first-page":"2104344","DOI":"10.1002\/advs.202104344","article-title":"A selective small\u2010molecule c\u2010Myc degrader potently regresses lethal c\u2010Myc overexpressing tumors","volume":"9","author":"Xu","year":"2022","journal-title":"Adv. Sci."},{"key":"B110","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3934\/publichealth.2022026","article-title":"Cutaneous malignant melanoma incidence is strongly associated with European depigmented skin type regardless of ambient ultraviolet radiation levels: evidence from worldwide population-based data","volume":"9","author":"You","year":"2022","journal-title":"AIMS Public Health"},{"key":"B111","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1101\/gad.350078.122","article-title":"Reducing MYC\u2019s transcriptional footprint unveils a good prognostic gene signature in melanoma","volume":"37","author":"Zacar\u00edas-Fluck","year":"2023","journal-title":"Genes. Dev."},{"key":"B112","doi-asserted-by":"publisher","first-page":"116675","DOI":"10.1016\/j.celrep.2025.116675","article-title":"A BRN2:MYC transcriptional axis regulates interconversion between therapy-resistant and tumorigenic phenotypes in melanoma","volume":"44","author":"Zhang","year":"2025","journal-title":"Cell. Rep."},{"key":"B114","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.1038\/s41598-025-90485-3","article-title":"Global, regional, and national trends in the burden of melanoma and non-melanoma skin cancer: insights from the global burden of disease study 1990\u20132021","volume":"15","author":"Zhou","year":"2025","journal-title":"Sci. Rep."},{"key":"B113","doi-asserted-by":"publisher","first-page":"6623","DOI":"10.1038\/onc.2008.258","article-title":"C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells","volume":"27","author":"Zhuang","year":"2008","journal-title":"Oncogene"}],"container-title":["Frontiers in Cell and Developmental Biology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1750941\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T05:39:21Z","timestamp":1785821961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcell.2026.1750941\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":118,"alternative-id":["10.3389\/fcell.2026.1750941"],"URL":"https:\/\/doi.org\/10.3389\/fcell.2026.1750941","relation":{},"ISSN":["2296-634X"],"issn-type":[{"value":"2296-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"article-number":"1750941"}}